Teva Pharmaceutical Industries Limited (TEVA) Management Discusses Q2 2013 Results (Webcast)

Aug. 1.13 | About: Teva Pharmaceutical (TEVA)

NuPathe (PATH): Q2 EPS of -$0.16 beats by $0.04. (PR)

The following audio is from an earnings conference call that began on August 1, 2013, at 8:00 AM ET. The audio is live-streaming while the call is active, and can be replayed upon its completion.